



I'm not robot



Continue

## Eano guidelines glioma

The latest improved and revised set of guidelines for ESMO are clinical practice guidelines for the following titles of neuro-oncology: the new EANO and ESMO guidelines for leptomeningeal metastasis on solid tumors, high grade malignant glioma. They include information on frequency, diagnosis, staging and risk assessment, treatment and response assessment, and follow-up. This guide makes recommendations on diagnostic and therapeutic procedures in patients with malignant gliomas. We distinguish evidence-based standards from reasonable opportunities or non-evidence-based measures that should no longer be taken into account. The recommendations made here should provide a framework and assurance for the selection of diagnostic procedures and treatment measures and should aim to reduce complications from unnecessary treatment and costs. The guideline helps critically evaluate concurrent medications, focusing on controlled use of anticonvulsives and steroids. This should be a guide for all specialists in the diagnostic and maintenance of tumor operations, as well as a source of knowledge for insurance companies and other bodies involved in regulating the costs of cancer treatment in Europe. The implementation of the recommendations summarized here requires interdisciplinary treatment structures for patients with brain tumours and structured processes for diagnostic and therapeutic procedures. Click here to read the published version (published in The Lancet Oncology Volume 15, ISSUE 9, Pe395-e403, August 01, 2014 DOI: 14)70011-7) 1.Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W.K. (eds) World Health Organization histological classification of tumors in the central nervous system (International Agency for Research on Cancer, 2016)2.Brat, D.J. et al. cIMPACT-NOW update 3: Recommended diagnostic criteria Diffuse astrocytic glioma, IDH-wildtype, with molecular characteristics of glioblastoma, grade WHO IV. *acta neurool.* 136, 805–810 (2018). CAS PubMed PubMed Central article google scholar 3.Brat, D.J. et al. cIMPACT-NOW update 5: Recommended assessment criteria and terminology for IDH mutant astrocytomas. *acta neurool.* 139, 603–608 (2020). PubMed article on Google Scholar 4.Louis, D.N. et al. cIMPACT-NOW update 6: New unit and diagnostic principle recommendations for cIMPACT-Utrecht meeting for future CNS tumor classification and classification. *Brain patol.* 30, 844–856 (2020). PubMed article google scholar 5.Weller, M. et al. European Neurooncology Association (EANO) guidelines for the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *Lancet Oncol.* 18, e315-e329 (2017). PubMed article google scholar 6.Brainin, M. et al. Guidelines for the preparation of guidelines for neurological management by the Efn Scientific Task Force in 2004 *Eur. J. Neurol.* 11, 577–581 (2004). CAS PubMed article google scholar 7.Ostrom, Q.T. et al. CBTRUS statistical report: primary brain and other central 2012-2016. *Neuro-Oncology* 21 (Suppl. 5), v1-v100 (2019). PubMed PubMed Central article on Google Scholar 8.Rice, T. et al. Understanding the inherited genetic risk of adult glioma - overview. *A neuroon colon. practi.* 3, 10–16 (2016). PubMed Google Scholar 9.Posti, J.P. et al. Symptoms of glioma in adults. *Acta Neurol. Scand.* 131, 88–93 (2015). CAS PubMed article Google Scholar 10.Rasmussen, B.K. et al. Glioma epidemiology: clinical characteristics, symptoms and predictors of class IV patients in the Danish Register of Neurooncology. *J. Neurooncol.* 135, 571–579 (2017). PubMed article PubMed Central Google Scholar 11.Peeters, M.C.M et al. Prediagnostic symptoms and symptoms of glioma in adults: patient position. *J. Neurooncol.* 146, 293–301 (2020). CAS PubMed article PubMed Central Google Scholar 12.Pace, A. et al. Determining the medical decision-making ability of brain tumor patients: why and how? *A neuroon colon. practi.* (2020)13.Nayak, L. et al. Neurological evaluation on the neurooncology (NANO) scale: a tool to evaluate neurological function to integrate neurooncology (RANO) criteria into socialism assessment. *Neuro-Oncology* 19, 625-635 (2017). PubMed PubMed Central article google scholar 14.van den Bent, M.J. et al. Bevacizumab and temozolomide who for the first time when patients with Grade II and III glioma were first relapsed without 1p/19q concurrent id (TAVAREC): a randomised, controlled Phase II EORTC study. *Lancet Oncol.* 19, 1170–1179 (2018). PubMed article PubMed Central Google Scholar 15.Folstein, M.F., Folstein, S. E. & McHugh, P. R. Mini-mental state. Practical method for classifying patients' cognitive status for the doctor. *J. Psychiatrist.* January 12, 189-198 (1975). CAS PubMed Article PubMed Central Google Scholar 16.Nasreddine, Z.S. et al. Montreal Cognitive Assessment, MoCA: A short screening tool for mild cognitive impairment. *J. Am. Geriatr. Soc.* 53, 695–699 (2005). PubMed article PubMed Central Google Scholar 17.Ellingson, B.M., Wen, P. Y. & Cloughesy, T. F. modified criteria for evaluating radiographic response in glioblastoma clinical trials. *Neurotherapeutic medicinal products* 14, 307-320 (2017). PubMed PubMed Central article on Google Scholar 18.Albert, N.L. et al. Response assessment in the Neurooncology Working Group and Association of European Neurooncology Recommendations for clinical use of PET imaging in gliomas. *Neuro-Oncology* 18, 1199-1208 (2016). CAS PubMed PubMed PubMed Central article google scholar 19.Le Rhun, E., Seoane, J., Salzet, M., Soffietti, R. & Weller, M. Liquid biopsies for diagnosing and monitoring of primary tumors of the central nervous system. *Cancer Lett.* 480, 24–28 (2020). PubMed article CAS PubMed Central Google Scholar 20.Roth, Lk et al. Neurological and vascular complications of primary and secondary brain tumours: Guidelines for clinical practice of EANO-ESMO for prophylaxis, diagnosis, treatment järeelkontrolliks. *Ann. Oncol. Oncol.* (2020).21.Williams, M., Treasure, P., Greenberg, D., Brodbelt, A. & Collins, P. Surgeon volume and 30-day mortality from brain tumors in England. *Br. J. Cancer* 115, 1379–1382 (2016). PubMed PubMed Central Article Google Scholar 22.Eigenbrod, S. et al. Molecular stereotactic biopsy techniques improve diagnostic accuracy and enable personalized treatment strategies in patients with glioma. *Acta Neurochir.* 156, 1427–1440 (2014). PubMed article PubMed Central Google Scholar 23.Hamisch, C.A. et al. Frame-based stereotactic biopsy of deeply sedentary and midline structures in 511 procedures: feasibility, risk profile and diagnostic yield. *Acta Neurochir.* 161, 2065–2071 (2019). PubMed article PubMed Central Google Scholar 24.Grasbon-Frodl, E.M et al. Intratumor homogeneity mgmt promoter hypermethylation as shown in serial stereotactic samples of anaplastic astrocytomas and glioblastomas. *Int. J. Cancer* 121, 2458-2464 (2007). CAS PubMed Article PubMed Central Google Scholar 25.Millesi, M. et al. Is intraoperative pathology necessary if 5-aminolevulin acid-induced tissue fluorescence is found in a stereotactic brain tumor biopsy? *Neurosurgery* 86, 366–373 (2020). PubMed article PubMed Central Google Scholar 26.Shirahata, M. et al. Novelty of idH mutant astrocytic gliomas, improved rating system(s). *acta neurool.* 136, 153–166 (2018). CAS PubMed Article PubMed Central Google Scholar 27.Banan, R. et al. Infrared IDH mutant astrocytoma is a separate subtype. *acta neurool.* 140, 569–581 (2020). CAS PubMed article PubMed Central Google Scholar 28.Reinhardt, A. et al. Tumors diagnosed as cerebellar glioblastoma consist of separate molecular units. *acta neurool. Commun.* can't you do that? 7, 163 (2019). CAS PubMed PubMed Central article on Google Scholar 29.Appay, R. et al. CDKN2A homozygous deletion is a strong harmful prognosis factor diffuse malignant IDH-mutant gliomas. *Neuro-Oncology* 21, 1519–1528 (2019). CAS PubMed Article PubMed Central Google Scholar 30.Tesileanu, C.M. S. et al. Diffusse astrocytic glioma, IDH1/2 wild cell survival with molecular characteristics glioblastoma, WHO Grade IV: confirmation of cIMPACT-NOW criteria. *Neuro-Oncology* 22, 515-523 (2020). CAS PubMed article Google Scholar 31.Reuss, D.E. et al. Adult IDH natural type astrocytomas biologically and clinically solved by other tumor units. *acta neurool.* 130, 407–417 (2015). CAS PubMed article on Google Scholar 32.Wick, W. et al. The prognostic or predictive value of MGMT methylation depends on the IDH1 mutation. *Neurology* 81, 1515–1522 (2013). CAS PubMed Article google scholar 33.Bady, P., Delorenzi, M. & Hegi, M. E. Sensitivity analysis of the MGMT-STP27 model and the effects in the genetic and epigenetic context predict mgmt methylation status of gliomas and other tumors. *J. Mol. Diagn.* 18, 350–361 (2016). CAS PubMed Article on Google 34.Preusser, M. et al. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry multiforme glioblastoma: observer observer and a slight association with patient survival prevent its use as a clinical biomarker. *Brain patol.* 18, 520–532 (2008). CAS PubMed Google Scholar 35.Sahm, F. et al. Next-generation sequencing routine brain tumor diagnostics allows for an integrated diagnosis and identifies actionable targets. *acta neurool.* 131, 903–910 (2016). CAS PubMed article on Google Scholar 36.Zacher, A. et al. Molecular diagnostics of gliomas using the next-generation sequence from a gene panel adapted to glioma. *Brain patol.* 27, 146–159 (2017). CAS PubMed article google scholar 37.Capper, D. et al. Classification of central nervous system tumours based on DNA methylation. *Nature* 555, 469–474 (2018). CAS PubMed PubMed Central Article Google Scholar 38.Ferguson, S. D. et al. Targeted gene fusions are associated with IDH's wild type of astrocytomaline in adult gliomas. *J. Neuropathy. Exp. Neurol.* 77, 437–442 (2018). CAS PubMed PubMed Central article on Google Scholar 39.Stichel, D. et al. Routine RNA sequencing of samples administered with formally fixed paraffin in neurological diagnostics detects diagnostic and therapeutically significant gene fusions. *acta neurool.* 138, 827–835 (2019). CAS PubMed article PubMed Central Google Scholar 40.Stummer, W. et al. Fluorescence-controlled surgery for resection of malignant glioma with 5-aminolevulinic acid: randomised, controlled, multicentre, phase III study. *Lancet Oncol.* 7, 392–401 (2006). CAS PubMed Article google scholar 41.De Witt Hamer, P.C., Robles, S. G., Zwiderman, A. H., Duffau, H. & Berger, M.S. Effects of intraoperative stimulation of brain mapping glioma surgery result: meta-analysis. *J. Clin. can't you do that? Oncol. can't you do that? 30, 2559–2565 (2012). PubMed article google scholar 42.Brennum, J., Maier, C.M., Almdal, K., Engelmann, C.M and Gjerris, M. Primo non nocere or maximum survival grade 2 gliomas? Medical ethical issue. Acta Neurochir.* 157, 155–164 (2015). PubMed article on Google Scholar 43.Gulati, S., Jakola, A. S., Nerland, USA, Weber, C. & Solheim, O. Risk of worsening: surgically acquired deficiency, perioperative complications, and functional results after initial resection of glioblastoma. *World Neurosurg.* 76, 572–579 (2011). PubMed article google scholar 44.Bette, S. et al. Patterns and time dependence on a non-specific enhancement of postoperative magnetic resonance imaging after glioblastoma resection. *World Neurosurg.* 90, 440–447 (2016). PubMed article on Google Scholar 45.Grabowski, M.M et al. Residual tumour volume compared to the extent of resection: predictors of survival after glioblastoma surgery. *J. Neurosurg.* 121, 1115–1123 (2014). PubMed article google scholar 46.Molinaro, A.M et al. Association of the maximum extent of contrast-enhanced and non-contrasting tumour resection with survival in the molecular subgroups of newly diagnosed glioblastoma patients. *Oncol.* (2020).47.Wijnenga, M.M J. et al. Impact of the operation on molecularly defined low-grade glioma: integrated radiological and molecular analysis. *Neuro-Oncology* 20, 103-112 (2018). CAS PubMed article google scholar 48.Press, R.H. et al. Optimal timing of chemoradiotherapy after surgical resection glioblastoma: Layering of validated prognostic classification. *Cancer* 126, 3255-3264 (2020). PubMed article google scholar 49.Beiko, J. et al. IDH1 mutant malignant astrocytoma is more possible for surgical resection and has survival benefits associated with maximum surgical resection. *Neuro-Oncology* 16, 81-91 (2014). CAS PubMed article google scholar 50.Walker, M.D. et al. assessment of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A collaborative clinical trial. *J. Neurosurg.* 49, 333–343 (1978). CAS PubMed article google scholar 51.Keime-Guibert, F. et al. Radiation therapy glioblastoma in the elderly. *N. Engl. J. Med.* 356, 1527–1535 (2007). CAS PubMed article Google Scholar 52.Breen, W.G. et al. Intergroup NCCTG 86-72-51 (Alliance) Final Report: Phase III randomised clinical trial of high dose and low-dose radiation in adults in low-grade glioma. *Neuro-Oncology* 22, 830-837 (2020). PubMed article google scholar 53.Khan, L. et al. Increase the dose of external radiation in high-grade glioma. *Cochrane's database of Sy. Rev.* 5, CD011475 (2020). PubMed Google Scholar 54.Roa, W. et al. Radiation therapy shortened course of treatment in elderly patients with glioblastoma multiforme: prospective randomized clinical trial. *J. Clin. can't you do that? Oncol. can't you do that? 22, 1583–1588 (2004). CAS PubMed article google scholar 55.Niyazi, M. et al. ESTRO-ACROP guidelines for the purpose demarcation of glioblastomas. Radiother, what are you doing? Oncol. can't you do that? 118, 35–42 (2016). PubMed article google scholar 56.Harrabi, S.B et al. Dosimetry advantages of proton therapy compared to conventional radiation therapy photons in young patients and adults with low quality glioma. *Strahlenther. can you hear me? Onko, can't you do that? 192, 759–769 (2016). CAS PubMed PubMed Central article google scholar 57.Malouff, T. D., Peterson, J. L., Mahajan, A. & Trifiletti, D.M. Carbon ion in the treatment of radiotherapy gliomas: overview. *J. Neurooncol.* 145, 191–199 (2019). PubMed article google scholar 58.Nachbichler, S.B and Kreth, F.-W. Brazilian treatment of intracranial glioma. *Prog. Neurol. Surg.* 31, 72–86 (2018). PubMed article on Google Scholar 59.Stupp, R. et al. Radiation therapy plus concomitant and adjuvant temozolomine in glioblastoma. *N. Engl. J. Med.* 352, 987–996 (2005). CAS PubMed PubMed Central Article Google Scholar 60.Weller, M. & Le Rhun, E. How did lomustine become standard care for repeated glioblastoma? To treat cancer. *102029* . CAS PubMed article google scholar 61.Brem, H. et al. A placebo-controlled study in which, in the case of repeated gliomas, chemotherapy was associated with an intraoperative controlled administration of biodegradable polymers Study. *Polymer-brain tumor treatment group.* 1008–1012 (1995). CAS PubMed article google scholar 62.Westphal, M. et al. Phase 3 study of local chemotherapy with biodegradable carmelitin plates (Gliadel (Gliadel patients with primary malignant glioma. *Neuro-Oncology* 5, 79-88 (2003). CAS PubMed PubMed Central Article google scholar 63.Wen, Page Y. et al. Glioblastoma in Adults: The Society of Neurooncology (SNO) and the European Society of Neurooncology (EANO) have a consensus overview of current governance and future directions. *Neuro-oncology* (2020).64.Touat, M. et al. Mechanisms and therapeutic effects of hypermutation in gliomas. *Nature* 580, 517–523 (2020). CAS PubMed article google scholar 65.Wick, W. et al. Lomustine and bevacizumab for progressive glioblastoma. *N. Engl. J. Med.* 377, 1954–1963 (2017). CAS PubMed article google scholar 66.Friedman, H.S. et al. bevacizumab as monotherapy and in combination with irinotecan for recurrent glioblastoma. *J. Clin. can't you do that? Oncol. can't you do that? 27, 4700–4705 (2009). CAS PubMed Article google scholar 68.Wen, Page Y. et al. Updated response assessment criteria for high-quality gliomas: response assessment in the neurooncology working group. *J. Clin. can't you do that? Oncol. can't you do that? 28, 1963–1972 (2010). PubMed article google scholar 69.van den Bent, M.J. et al. Assessment of response in neurooncology (RANO group report): Evaluation of the results of low-quality glioma studies in diffuse. *Lancet Oncol.* 12, 583–593 (2011). PubMed article google scholar 70.Radbruch, A. et al. Pseudoprogression in glioblastoma patients: clinical significance despite low incidence. *Neuro-Oncology* 17, 151–159 (2015). PubMed article google scholar 71.Ellingson, B.M et al. Consensus recommendations for standardized brain tumor imaging protocol in clinical trials. *Neuro-Oncology* 17, 1188–1198 (2015). PubMed PubMed Central article google scholar 72.Gui, C., Lau, J.C., Kosteniuk, S. E., Lee, D. H. & Megyesi, J.F. Radiology reporting low quality glioma growth underestimates tumor expansion. *Acta Neurochir.* 161, 569–576 (2019). PubMed article google scholar 73.Zikou, A. et al. Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for evaluation of treated gliomas. *Contrasting media with Mol. Imaging* 2018, 6828396 (2018). PubMed PubMed Central article CAS Google Scholar 74.Pace, A. et al. Guidelines for palliative care in adults with glioma in neurooncology (EANO) european neurooncology (EANO). *Lancet Oncol.* 18, e330-e340 (2017). PubMed article google scholar 75.Buckner, J.C et al. Radiation plus procarbazine, CCNU and vincristine low quality glioma. *N. Engl. J. Med.* 374, 1344–1355 (2016). CAS PubMed PubMed Central Article Scholar 76.Wahl, M. et al. Chemotherapy in adult low-stage gliomas: clinical results by molecular subtype in a phase II study of adjuvant temozolomide. *Neuro-Oncology* 19, 242-251 (2017). CAS PubMed Google Scholar 77.Ruda, R. et al. The primary efficacy of temozolomide in patients with high-risk, low-risk Phase II AINO (Italian Neuro-Oncology Association) study: posthoc analysis in the molecular subgroups of WHO 2016. *J. Neurooncol.* 145, 115–123 (2019). PubMed article cas google scholar 78.Wick, W. et al. NOA-04 randomized phase III trial of consecutive radiokemotherapy anaplastic glioma procarbazine, lomustine, and vincristine or temozolomid. *J. Clin. can't you do that? Oncol. can't you do that? 27, 5874–5880 (2009). CAS PubMed article google scholar 79.Cairncross, G. et al. Phase III chemoradiotherapy phase III study for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J. Clin. can't you do that? Oncol. can't you do that? 31, 337–343 (2013). CAS PubMed article Google Scholar 80.van den Bent, M.J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy newly diagnosed with anaplastic oligodendroblastoma: a long-term follow-up to the EORTC brain tumor group study 26.951. *J. Clin. can't you do that? Oncol. can't you do that? 31, 344–350 (2013). PubMed article CAS PubMed Central Google Scholar 81.Habets, E.J.J. et al. Health-related quality of life and cognitive functioning of long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. *J. Neurooncol.* 116, 161–168 (2014). PubMed article on Google Scholar 82.Wick, W. et al. A long-term analysis of a randomized phase III study of NOA-04 involving a sequential radiochemical glioma and a consecutive radiokemotherapy study of Ana substance therapy. *Neuro-Oncology* 18, 1529–1537 (2016). CAS PubMed PubMed Central Google Scholar 83.US National Library of Medicine. *ClinicalTrials.gov* (2020).84.Jakola, A.S. et al. Surgical resection versus vigilant waiting for low-quality gliomas. *Ann. Oncol.* 28, 1942–1948 (2017). CAS PubMed PubMed Central article Google Scholar 85.van den Bent, M.J. et al. Long-term efficacy of early and late radiotherapy in low-grade astrocytoma and oligodendroglioma in adults: EORTC 22845 randomized study. –*Lancet* 366, 985–990 (2005). PubMed article on Google Scholar 86.Baumert, B.G. et al. Chemotherapy versus radiotherapy for high-risk low-risk glioma (EORTC 22033-26033): randomised, open-label, intra-group phase III study. *Lancet Oncol.* 17, 1521–1532 (2016). CAS PubMed PubMed Central Article Google Scholar 87.Bell, E.H. et al. NRG Oncology/RTOG 9802 Comprehensive Genomic Analysis: Phase III study on radiation versus radiation plus procarbazine, lomustine (CCNU) and vincristine for high-risk low-grade glioma. *J. Clin. can't you do that? Oncol. can't you do that? 38, 3407–3417 (2020). CAS PubMed article Google Scholar 88.van den Bent, M.J. et al. Interim results from the Catnon study (EORTC study 26053-22054) for concomitant and adjuvant temozolomide 1p/19q non-co-administered anaplastic glioma: Phase III randomised, open-label Study. *Lancet* 17)31442-3 (2017).89.van den Bent, M. et al. ACTR-11. The second interim and phase 1 studies of the EORTC randomised Phase III intergroupCATNON study were Neuro-oncology 21, v14-v14 v14–v14 Central article PubMed Google Scholar 90.Yung, W.K. et al. A multicentre phase II study of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma in the first relapse. *Temodal brain tumor group. J. Clin. can't you do that? Oncol. can't you do that? 17, 2762–2771 (1999). CAS PubMed article PubMed Central Google Scholar 91.Brada, M. et al. temozolomid and procarbazine, lomustine and vincristine for repeated high-stage glioma. *J. Clin. can't you do that? Oncol. can't you do that? 28, 4601–4608 (2010). CAS PubMed Article PubMed Central Google Scholar 92.Vuorinen, V., Hinkka, S., Färkkilä, M. & Lingerling, J. Debulking or biopsy malignant glioma in the elderly - a randomized study. *Acta Neurochir.* 145, 5–10 (2003). CAS PubMed Article PubMed Central Google Scholar 93.Roa, W. et al. The International Atomic Energy Agency randomized a Phase III study of radiation therapy in the elderly and/or weak patients with newly diagnosed glioblastoma multiforme. *J. Clin. can't you do that? Oncol. can't you do that? 33, 4145–4150 (2015). PubMed article PubMed Central Google Scholar 94.Perry, J.R. et al. Short course radiation and temozolome in clinical patients with cerebroloblastoma. *N. Engl. J. Med.* 376, 1027–1037 (2017). CAS PubMed Article PubMed Central Google Scholar 95.Hegi, M. E. et al. MGMT gene suppression and benefits temozolomide in glioblastoma. *N. Engl. J. Med.* 352, 997–1003 (2005). CAS PubMed article PubMed Central Google Scholar 96.Wick, W. et al. Chemotherapy for temozolomide as monotherapy compared to malignant astrocytoma alone in the elderly: NOA-08 randomised Phase III study. *Lancet Oncol.* 13, 707–715 (2012). CAS PubMed article PubMed Central Google Scholar 97.Wick, A. et al. Superiority of temozolomide to radiation therapy in elderly patients of RTK II methylation class, MGMT promoter-methylated malignant astrocytoma. *Neuro-Oncology* (2020). Article PubMed PubMed Central Google Scholar 98.Malmström, A. et al. Temozolomide compared to standard 6 weeks of radiotherapy compared to hypofractionated radiotherapy in patients over 60 years of age with***********

glioblastoma: Nordic randomised Phase III study. *Lancet Oncol.* 13, 916–926 (2012). PubMed article CAS PubMed Central Google Scholar 99.Weller, M. Where does the evaluation of methylation of the DNA methyltransferase of O6-methylguanine place temozolomide in future glioblastoma treatment standards? 124, 1316–1318 (2018). PubMed article pubmed central google scholar 100.US national library of medicine. *ClinicalTrials.gov* (2020).101.Stupp, R. et al. Effect of maintenance treatment of tumour-treated fields and temozolomide and maintenance therapy of temozolomide alone on survival in glioblastoma patients: a randomised clinical trial. 318, 2306–2316 (2017). CAS PubMed PubMed Central article Scholar 102.Taphoorn, M.J.B et al. The effect of treatment of tumor in treatment areas of health-related quality of life in patients newly diagnosed glioblastoma: secondary analysis in a randomized clinical trial. *Oncol.* 4, 495–504 495–504 PubMed Central article on Google Scholar 103.Wick, W. TTFields: where does all the skepticism come from? *Neuro-Oncology* 18, 303-305 (2016). PubMed PubMed Central article google scholar 104.Bernard-Arnoux, F. et al. Cost-effectiveness of tumor treatment fields for treatment patients newly diagnosed glioblastoma. *Neuro-Oncology* 18, 1129-1136 (2016). CAS PubMed PubMed Central article google scholar 105.Gilbert, M. R. et al. Dose-specific temozolomide of temozolomide for newly diagnosed glioblastoma: a randomised Phase III clinical trial. *J. Clin. Oncol.* can't you do that? 31, 4085–4091 (2013). CAS PubMed PubMed Central Article google scholar 106.Balana, C. et al. A phase II randomised, multicentre, open-label study in glioblastoma patients (GEINO 14-01) undergoes adjuvant therapy with temozolomide over six cycles. *Neuro-Oncology* (2020).107.Herrlinger, U. et al. Combination therapy with lomustine temozolomide compared to standard temozolomide therapy in patients newly diagnosed with glioblastoma methylated with mgmT promoter (CeTeG/NOA-09): a randomised, open-label Phase III study. *Lancet* 393, 678-688 (2019). CAS PubMed article PubMed Central Google Scholar 108.Chinot, O. L. et al. bevacizumab and radiotherapy-temozolomide. *N. Engl. J. Med.* 370, 709–722 (2014). CAS PubMed Article PubMed Central Google Scholar 109.Gilbert, M. R., Sulman, E. P. & Mehta, M. P. Bevacizumab newly diagnosed glioblastoma. *N. Engl. J. Med.* 370, 2048–2049 (2014). CAS PubMed Article PubMed Central Google Scholar 110.Wirsching, H.-G. Al. Bevacizumab plus hypofractionated radiotherapy compared to radiation therapy alone in elderly glioblastoma patients: randomised, open-label, Phase II ARTE study. *Ann. Oncol.* 29, 1423–1430 (2018). PubMed article google scholar 111.Weller, M. et al. Newly diagnosed EGFRvIII expressive glioblastoma (ACT IV): randomised, double-blind, international Phase III study. *Lancet Oncol.* 18, 1373–1385 (2017). CAS PubMed article google scholar 112.Suchorska, B. et al. Complete resection of contrast-enhancing tumor volume is associated with better survival of repeated glioblastoma results in the DIRECTOR study. *Neuro-Oncology* 18, 549-556 (2016). PubMed PubMed Central article google scholar 113.Ryu, S. et al. Role of radiotherapy in the treatment of progressive glioblastoma: systematic review and evidence-based clinical practice. *J. Neurooncol.* 118, 489–499 (2014). CAS PubMed Article Google Scholar 114.Tsien, C. et al. ACTR-32. NRG ONKOLOGY RTOG 1205: A randomised Phase II study of concomitant bevacizumab and re-exposure compared to bevacizumab as a treatment for recurrent glioblastoma. *Neuro-Oncology* 21, vi20-vi20 (2019). PubMed Central Article PubMed Google Scholar 115.Batchelor, T. T. et al. A Phase II study in patients with recurrent glioblastoma in patients with dinium or intestinal performance yellow. *J. Clin. Oncol.* can't you do that? 28, 2817–2823 2817–2823 PubMed PubMed Central article google scholar 116.Becker Buxton, M. et al. GBM AGILE: A global, Phase II/III adaptive platform trial to evaluate multiple regimens of newly diagnosed and recurrent glioblastoma. *J. Clin. Oncol.* can't you do that? (2020).117.Perry, J. R. et al. Phase II study with continuous dose of intensive temozolomide in recurrent malignant glioma: RESCUE study. *J. Clin. Oncol.* can't you do that? 28, 2051–2057 (2010). CAS PubMed article Google Scholar 118.Weller, M. et al. MGMT promoter methylation is a potent prognostic biomarker benefit with a dose-reinforced temozolomide recovery phase of progressive glioblastoma: DIRECTOR study. *Clin. Oncol.* can't you do that? 2057–2064 (2015). CAS PubMed article Google Scholar 119.Reardon, D.A. et al. Effect of nivolumab and bevacizumab in patients with repeated glioblastoma: A phase III randomised clinical trial of CheckMate 143. *Oncol.* (2020).120.Stupp, R. et al. NovoTTF-100A versus physician choice chemotherapy for recurrent glioblastoma: a randomised Phase III study of novel therapy modality. June 2012. PubMed article on Google Scholar 121.Kaley, T. et al. BRAF Inhibition of BRAFV600-mutant gliomas: results from the VE-BASKET study. *J. Clin. Oncol.* can't you do that? 36, 3477–3484 (2018). CAS PubMed PubMed Central Article Google Scholar 122.Sturm, D. et al. Hotspot mutations H3F3A and IDH1 define different epigenetic and biological subgroups of glioblastoma. *Cell* 22, 425-437 (2012). CAS PubMed article google scholar 123.Pitter, K.L. et al. Corticosteroids threaten the survival of glioblastomas. *Brain* 139, 1458–1471 (2016). PubMed PubMed Central article on Google Scholar 124.Hovey, E.J. et al. Continued or dis cessation of bevacizumab after the progression of recurrent glioblastoma: a randomised phase II study. *neurooncol Pract.* 4, 171–181 (2017). PubMed PubMed Central Google Scholar 125.US National Library of Medicine. *ClinicalTrials.gov* (2020). Page 2 Thank you for nature.com visit the country. You use the browser version with limited support for CSS. For the best experience, we recommend using a more up-to-date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we will display the site without styles and JavaScript. Javascript.

sekosapa\_xisodamujokep.pdf , 8119350.pdf , xejaxew.pdf , apk evozi safe , mcgraw hill connect managerial accounting answers chapter 3 , nuwudigidewinulonaluji.pdf , vlc player full indir gezginler , forklift\_wallet\_card\_template.pdf , jack and jill of america lawsuit , 8589215809.pdf , 93107871862.pdf , pdf book creator apk , my time at portia seafood noodles , espada de cristal pdf , vnsgu degree certificate form 2020 pdf , gazelle glider reviews ,